Keywords: Tibotec, Johnson & Johnsonm Mylan, Matrix, Hetero Drugs, Aspen, HIV drug, Rilpivirine, Sub-Saharan Africa, India, Generic, Licensing
J&J unit Tibotec signs multiple deals with generic drugmakers for access to new HIV treatment rilpivirine pre-approval
Article | 31 January 2011
Ireland-based Tibotec Pharmaceuticals, a subsidiary of US health care major Johnson & Johnson (NYSE: JNJ), has granted multiple non-exclusive licenses ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
